Screener
Kyverna Therapeutics, Inc. KYTX Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 41,367 | 47,408 |
| Loss from operations | (41,367) | (47,408) |
| Interest income | 2,327 | 2,825 |
| Interest expense | (667) | (25) |
| Other expense, net | (21) | (27) |
| Total other income, net | 1,639 | 2,773 |
| Net loss | (39,728) | (44,635) |
| Other comprehensive loss |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s interest expense?
- Kyverna Therapeutics, Inc. (KYTX) reported interest expense of $667K in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s interest expense changed year-over-year?
- Kyverna Therapeutics, Inc.'s interest expense increased by 2568.0% year-over-year, from $25K to $667K.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s interest expense?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s interest expense has grown at a 61.9% compound annual growth rate (CAGR), from $187K to $490K.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Kyverna Therapeutics, Inc.'s interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude